Natasha Sheybani, PhD (Photo by Tom Cogill for UVA Engineering)
Natasha Sheybani PhD, an assistant professor of biomedical engineering at the University of Virginia School of Engineering and School of Medicine, will collaborate with researchers at Children’s National Hospital to study the combination of two therapies for pediatric brain cancer.
High-risk brain tumors in children often don’t respond well to existing chemotherapy and radiation treatments, but Sheybani and her collaborators hope their fusion of therapies will offer a better option.
Over the two-year project, researchers will investigate the use of chimeric antigen receptor T-cell therapy, a type of immunotherapy that uses the body’s immune system to destroy tumors, and low-intensity focused ultrasound, which non-invasively directs sound waves toward targeted organs of the body. By combining the best of both therapies, they aim to trigger an immune response in the brain and help CAR T-cells fight off the cancer.
The project will initially focus on the “sonic hedgehog” and “group 3” subtypes of medulloblastoma, the most common pediatric brain malignancy. Both sonic hedgehog, named for the video game character due to the spiky protrusions on the protein, and group 3 subtypes are often fatal using existing treatments. Researchers hope their combined treatment will improve survivorship.
3D rendering of hedgehog protein
“Children with brain cancer represent a particularly vulnerable patient population in urgent need of far more effective and far less toxic treatment options,” said Sheybani. “We hope to deliver on that need by converging a powerful combination of therapies for the first time, in a unique set of preclinical models that faithfully recapitulate human disease.”
The research is funded by a $600,000 Idea Award, administered by the U.S. Department of Defense. Idea Awards are prestigious grants that support high-risk, potentially high-reward research that fills gaps in cancer prevention and treatment.
Sheybani’s collaborators include Dalia Haydar, assistant professor of pediatrics at the George Washington University School of Medicine and Health Sciences, and Yanxin Pei, associate professor of pediatrics at George Washington University. Both researchers are faculty members at Children’s National Hospital.
Non-invasive Precision Cancer Management
The Sheybani Lab at the University of Virginia is working at the nexus of therapeutic ultrasound, advanced imaging and tumor immunology to design and deploy precision cancer immunotherapy paradigms. The group seeks to advance the role of focused ultrasound (FUS) for immuno-modulation and immunotherapy delivery in solid cancers of the brain and periphery. Learn more
UVA Focused Ultrasound Cancer Immunotherapy Center
UVA’s FUS Cancer Immunotherapy Center’s mission is to accelerate the discovery and translation of therapeutic FUS immuno-oncology strategies for a number of cancer indications. Learn more
Reprinted from UVA Engineering.
Filed Under: Research